Menu
Search
|

Menu

Close
X

Syros Pharmaceuticals Inc SYRS.OQ (NASDAQ Stock Exchange Global Select Market)

10.05 USD
-0.04 (-0.40%)
As of 8:59 PM GMT
chart
Previous Close 10.09
Open 10.06
Volume 25,054
3m Avg Volume 103,770
Today’s High 10.34
Today’s Low 9.99
52 Week High 24.35
52 Week Low 6.31
Shares Outstanding (mil) 26.26
Market Capitalization (mil) 420.43
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 7 analysts

KEY STATS

Revenue (mm, USD)
FY17
1
FY16
0
FY15
0
EPS (USD)
FY17
-1.015
FY16
-1.999
FY15
-1.527
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
296.49
5.77
Price to Book (MRQ)
vs sector
4.61
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
0.15
16.52
LT Debt to Equity (MRQ)
vs sector
0.01
12.22
Return on Investment (TTM)
vs sector
-68.14
14.43
Return on Equity (TTM)
vs sector
-442.37
16.13

EXECUTIVE LEADERSHIP

Peter Wirth
Independent Chairman of the Board, Since 2017
Salary: --
Bonus: --
Nancy Simonian
Principal Financial Officer, Director, Since 2017
Salary: $473,260.00
Bonus: --
Kyle Kuvalanka
Chief Operating Officer, Since
Salary: $380,000.00
Bonus: --
Colleen DeSimone
Principal Accounting Officer, Since 2017
Salary: --
Bonus: --
Eric Olson
Chief Scientific Officer, Since
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

620 Memorial Dr Ste 300
CAMBRIDGE   MA   02139-4815

Phone: +1617.7441340
Site: syros.com/

Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines. The Company's drug programs include SY-1425 (retinoic acid receptor alpha (RARa) agonist) and SY-1365 (cyclin-dependent kinase 7 (CDK7) inhibitor). SY-1425 (tamibarotene) is an oral, potent and selective agonist, or activator, of the transcription factor RARa. SY-1365 is a small molecule inhibitor of the transcriptional kinase known as CDK7. The Company is using its platform to analyze gene expression programs across additional cancers, inflammatory diseases and other diseases to identify optimal points of therapeutic intervention in specific subsets of patients.

SPONSORED STORIES